Skip to main content

Table 3 Multivariate associations with successful TNFi discontinuation with and without MBDA score as a predictor

From: Predictors of biologic-free disease control in patients with rheumatoid arthritis after stopping tumor necrosis factor inhibitor treatment

 

With MBDA

Without MBDA

Predictor

OR

95% CI

P

OR

95% CI

P

anti-TNF monoclonal antibodya

2.41

1.58–3.67

< 0.0001

2.46

1.61–3.73

< 0.0001

Disease duration < 10 yrs.

2.15

1.42–3.26

< 0.0001

2.14

1.42–3.23

< 0.0001

MBDA score ≤ 44

2.00

1.10–3.64

0.023

  1. aReference category is receptor antagonist
  2. TNFi tumor necrosis factor-alpha inhibitors, MBDA multi-biomarker disease activity, OR Odds ratio. Hosmer and Lemeshow with MBDA χ2(5) = 1.57, P = 0.905, area under ROC curve = 0.66 (95% CI: 0.61–0.71, P < 0.0001); Hosmer and Lemeshow without MBDA χ2(2) = 0.00, P = 1.000, area under ROC curve = 0.65 (95% CI: 0.59–0.70, P < 0.0001)